|
Therapy of B-Cell Acute Lymphoblastic Leukemia: An Evolving Landscape
Presented by Amir Fathi, MD, Associate Professor of Medicine at Harvard Medical School, this activity will highlight individualized treatment selection for patients with acute lymphoblastic leukemia (ALL), as well as recent efficacy and safety data for novel therapeutic strategies. Start the activity now.
STATEMENT OF NEED
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the proliferation of immature lymphoid cells throughout the bone marrow and blood (Rana... |
|
|
Improving Outcomes in Hodgkin Lymphoma
This in-depth discussion, presented by Louis Diehl, MD, Professor of Medicine at Duke University Medical School, will feature strategies for incorporating predictive and prognostic markers, recent efficacy and safety data, and adverse event management strategies into treatment selection for patients with Hodgkin lymphoma (HL). Start the activity now.
STATEMENT OF NEED
Hodgkin lymphoma (HL) is a rare malignancy of the lymph nodes and lymphatic system, with about 8,830 new cases diagnosed ... |
|
|
Diagnosis and Evidence-Based Management of T-Cell Lymphoma
STATEMENT OF NEED
T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States (LRF, 2022). Compared with its B-cell counterpart, TCL has a poor prognosis and is associated with a 5-year survival rate of less than 20%. The clinical and pathologic presentations of TCL are varied and often nonspecific, making diagnosis and treatment challenging (Salem et al, 2021). In this webinar, Aaron Goodman, MD, will update clinic... |
|
|
Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors: Emerging Combinations for Newly Diagnosed CLL High-Risk Relapsed/Refractory (R/R) CLL
Target Audience The intended audience for this activity are hematologic oncologists, hematologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL. Learning Objectives Upon completion of this activity, participants should be better able to: Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies List the emerging combination regimens, including BTK inhi... |
|
|
Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors: Patient Selection
Target Audience
The intended audience for this activity are hematologic oncologists, hematologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL.
Learning Objectives
Upon completion of this activity, participants should be better able to:
Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies
List the emerging combination regimens, including... |
|
|
Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors: Aligning Patient and Provider Goals
Target Audience
The intended audience for this activity are hematologic oncologists, hematologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL.
Learning Objectives
Upon completion of this activity, participants should be better able to:
Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies
List the emerging combination regimens, including... |
|
|
Follicular Lymphoma: Answers to Important Nursing Questions
Target Audience
This activity is designed to meet the educational needs of oncology nurses, nurse practitioners and navigators engaged in the care of patients with follicular lymphoma.
Program Overview
Advances in the treatment of FL have led to the approval of two novel agents as well as updates to clinical practice guidelines. Oncology nursing professionals have unique and often long-standing relationships with their FL patients and are trusted sources of information and support. Th... |
|
|
Identifying Actionable Markers to Guide Therapy for Patients With EGFR-Mutant NSCLC
This interactive digital activity combines animated slides and expert video commentary on molecular testing recommendations, guidance on interpreting molecular testing results, and clinical trial evidence to enhance the implementation of precision medicine in the care of patients with EGFR-mutant NSCLC. Through this education, learners explore best practices for EGFR mutation testing, application of clinical trial data to treatment selection, and the role of concurrent mutations in the prognos... |
|
|
Targeted Therapies in CLL/SLL: Treatment Sequencing and Adverse Events Management
B-cell non-Hodgkin lymphoma management has advanced significantly in recent years, and patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have been beneficiaries of these advances. However, studies have shown that as many as 40% of patients with CLL/SLL undergoing treatment with novel agents discontinue therapy—the majority of which do so because of adverse events (AEs)—and data suggest that the management of AEs is not consistent with recommendations. Moreover... |
|
|
Updates in Mantle Cell Lymphoma
Discover insights on predictive and prognostic markers, emerging efficacy and safety data, strategies to optimize tolerability for patients receiving novel therapies for mantle cell lymphoma (MCL), and more in this case-based activity presented by John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine. Start the activity now.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is an aggressive variant of B-cell non-Hodgkin ly... |
|
|
Treatment Advances in Waldenstrom Macroglobulinemia
In this case-based discussion, Morie Gertz, MD, Chair of General Internal Medicine at the Mayo Clinic in Minnesota, will discuss how to use predictive and prognostic markers to select treatment for patients with Waldenstrom macroglobulinemia (WM) and how to appraise emerging clinical trial data and adverse event management strategies for novel treatments. Start the activity now.
STATEMENT OF NEED
Waldenstrom macroglobulinemia (WM) is a rare cancer of B lymphocytes associated with lymphop... |
|
|
Ace the Case: Disease Progression in a 65-Year-Old Man With Previously Treated Mantle Cell Lymphoma
This activity utilizes a case study to discuss treatment options for an older patient with relapsed mantle cell lymphoma (MCL). |
|
|
CAR-T Therapy: What’s in the CARds? – Module 1
Target Audience
This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.
Program Overview
This activity provides an overview of CAR T-cell development, available CAR T-cell products for blood cancers, and important side effects of CAR T-cell therapy.
Learning Objective
Upon completion of this activity, participants should be better able to:
... |
|
|
AML 2021: Strategies for Attack Before Diagnosis and After Remission – Module 2
Target Audience
This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.
Program Overview
This activity provides an overview of important genetic mutations in acute myeloid leukemia and recent therapeutic advances.
Learning Objective
Upon completion of this activity, participants should be better able to:
Identify the impact of minimal resid... |
|
|
Efficacy of Targeted Therapy in Genetic Subtypes of Aggressive Lymphoma – Module 3
Target Audience
This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.
Program Overview
This activity provides an overview of molecular and clinical subtypes of lymphoma and the mechanisms by which targeted therapies work for molecular subtypes.
Learning Objective
Upon completion of this activity, participants should be better able to:
Sum... |
|
|
Novel Therapeutic Strategies in Myeloma – Module 4
Target Audience
This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.
Program Overview
This activity provides an overview of recent therapeutic advances for patients with newly diagnosed or relapsed multiple myeloma and the mechanisms by which novel therapies work.
Learning Objective
Upon completion of this activity, participants should be b... |
|
|
COVID-19, Vaccinations, and Blood Cancer Patients: The LLS Registry and Q&A – Module 5
Target Audience
This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.
Program Overview
This activity provides a review of data from the Leukemia & Lymphoma Society patient registry on SARS-CoV-2 vaccination in patients with blood cancer and audience Q&A.
Learning Objective
Upon completion of this activity, participants should be better able ... |
|
|
Key Questions Answered in the Management of Follicular Lymphoma
Advances in the treatment of FL have led to the approval of two novel agents and updates to clinical practice guidelines. Nurses have unique and often long-standing relationships with their patients who have FL and are trusted sources of information and support. Oncology nurses who care for patients with FL should be aware of treatment guideline changes and their impact on clinical practice. Recently approved novel medications are associated with unique toxicities that differ from standard che... |
|
|
Management of Large B-Cell Lymphomas: A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-Cell Therapy
TARGET AUDIENCE:
Hematologist-oncologists, pathologists, histologists, advanced practitioners, oncology nurses, pharmacists, and other healthcare professionals involved in the care of patients diagnosed with LBCL.
PROGRAM OVERVIEW:
In this activity, Jeremy Abramson, MD, highlights the significant disease burden of B-cell lymphomas, as well as the latest advances in therapeutics, and practical strategies for integrating novel therapies into practice through patient selection and supportive c... |
|